chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Mom reports 1st immun given 230PM 19FEB91; pt slept but was crying/fussy from 5-6PM that nite; From 6-10PM pt was not consolable, would not nurse, walking did not help; Mom gave APAP q4hrs; No redness at site, no fever;
This spontaneous case was reported by a consumer and describes the occurrence of HAND DERMATITIS (eczema on her hand), PRURITUS (eczema on her hands that is itchy), CHONDROCALCINOSIS PYROPHOSPHATE (knee pain diagnozed as pseudo-gout), ERYTHEMA (eczema on her hands that is red) and RASH (Rash) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 041B21A and 031A21A) for COVID-19 vaccination. No Medical History information was reported. On 17-Mar-2021 at 9:40 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021 at 9:40 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HAND DERMATITIS (eczema on her hand), PRURITUS (eczema on her hands that is itchy), CHONDROCALCINOSIS PYROPHOSPHATE (knee pain diagnozed as pseudo-gout), ERYTHEMA (eczema on her hands that is red) and RASH (Rash). At the time of the report, HAND DERMATITIS (eczema on her hand), PRURITUS (eczema on her hands that is itchy), CHONDROCALCINOSIS PYROPHOSPHATE (knee pain diagnozed as pseudo-gout), ERYTHEMA (eczema on her hands that is red) and RASH (Rash) had not resolved. No Concomitant medication was reported. Treatment medication included topical, homeopathic cream  which has been helping with eczema. Patient applies that cream every time she washes her hands. She also has been using a body lotion bar which has been helping with the itching. Patient's rash becomes worse if she does not get enough sleep, and it gets better when washing her hands using the water.
A 59 year old male pt experienced severe abdominal pain and pancreatitis, which resulted in prolonged hospitalization one day after receiving the Fluvirin vaccine on 08-OCT-2001. At the time of reporting the pt was recovering. There was insufficient information to determine the reporter's causality assessment.
October 16th immediately after shots he cried for 4 hours straight then that same night at 10 pm he started projectile vomiting which lasted for 5 hours. October 17th he had diarrhea and a fever which lasted until October 20th. October 19th to November 3rd he had a severe cold. November 10th he got an ear infection and after 2 rounds of antibiotics still was not gone until November 29th which he still had fluid in his ears but was not considered to be a infection. December 10th he started having random and reoccurring fevers that's lasted 2-3 days anywhere from 99° F to 103° F. Fevers were once a month then every 2 weeks with the most recent being 3 days within each other. December 10th-12th Fever January 12-14th fever February 14-17th fever February 27-30th fever March 11-12th Fever March 15-17th Fever.
Dizziness, NauseaVomiting, FATIGUE Narrative: MISSED WORK DUE TO SYMPTOMS
pt experienced shortness of breath, chest pain, Hheadache, palpitations, nausea, abdominal pain within 1/5-2 hours of injection
Administered Moderna vaccine after the beyond-use-date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered Moderna vaccine after the beyond-use-date) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered Moderna vaccine after the beyond-use-date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered Moderna vaccine after the beyond-use-date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported by reporter No treatment medications provided by the reporter.   Reporter administered some Moderna vaccines after the beyond-use-date, after the 30 days.   Most recent FOLLOW-UP information incorporated above includes: On 20-Dec-2021: Follow up received-batch number updated.
Breakthrough COVID first dose 4/3/2021.   Patient is a fully vaccinated 66-year-old male with past medical history of Parkinson's, CVA with residual right-sided weakness, DM 2, HTN, and anxiety/depression who presents with generalized weakness. Patient with 9 day history of positive COVID test and symptoms including but not limited to nonproductive cough, congestion, slight fever, fatigue, SOB, confusion, and dizziness.  For the past 3 days patient has been increasingly fatigued unable to get out of bed.
My are was sore for a week then my arm pit hurt for 3 days and a red rash/hive appeared at the injection site.
I noticed I was getting shortness of breath and dizzy and it was in the afternoon 11/16/2021. I did use my inhaler and it did seem to help relieve my symptoms somewhat temporarily. I went ahead and scheduled an appointment with my provider, and with my symptoms, I took prednisone. On Wednesday, I followed up with him and I ended up taking prednisone for 12 days and taper. Before I saw him on Wednesday, I was also experiencing dizziness here and there. I felt like I was really slow and sluggish. My symptoms continued into Thursday with the dizziness and sluggishness. I did start to feel better on Friday, but I did miss work Thursday & Friday because of the symptoms. Since I've gotten the vaccination, I've gotten dizziness here and there. But that was the first time I had to get attention for it because of the shortness of breath with the symptoms as well as the sluggishness.
The wrong pfizer vial was grabbed from the refrigerator and a pediatric pfizer dose was administered to an adult this morning. When the wrong vial was drawn up, the regular pfizer vaccine label was attached to the syringe. The patient received less than the recommended 30mcg per dose of the adult vaccine. Based on CDC Interim Clinical Considerations, we told the patient that she can return for a repeat dose today. Pt said she will come back tonight.
This case was reported by a nurse via a wholesaler sales representative and described the occurrence of low seroconversion to hepatitis b vaccine in a subject of unspecified age and gender who was vaccinated with Engerix-B for prophylaxis. It was thougth that the subject completed the entire series of Engerix-B (vaccination date not provided), but it was unclear. At an unspecified time after vaccination with Engerix-B, the subject's titer did not reach the correct level, and the subject developed possible lack of efficacy. At the time of reporting, the outcome of the events was unspecified.
This spontaneous report as received from a health care worker refers to unspecified number of patients of unknown age. On unknown dates the patients was vaccinated with (Oka/Merck) VARIVAX (dose, frequency, lot # K003412 and expiration date were unknown 06-MAR-2014). On unknown date the patients experienced redness and swelling at the injection site. The outcome of redness and swelling at the injection site was unknown. Additional information has been requested.
Patient developed hives, angioedema, and arthralgias as well as chest pain beginning 7-9-11 leading to hospitalization on 7-10-11. Treated with antihistamines and prednisone. Discharged 7-15-11. Recovered. last seen 7/22/11.
Pt noticed 3/29/05 redness with itching that increased over time. In clinic 4/1/05 had redness of 10cm with induration 3cm. Benadryl and Ibuprofen. Prescribed by PA. Rtc 4/5/05 if not improved.
Headache; Joint Pain; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), ARTHRALGIA (Joint Pain) and FATIGUE (Fatigue) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced HEADACHE (Headache), ARTHRALGIA (Joint Pain) and FATIGUE (Fatigue). At the time of the report, HEADACHE (Headache), ARTHRALGIA (Joint Pain) and FATIGUE (Fatigue) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant drugs was provided No treatment information was provided.
She developed a runny nose and mild headache. No fevers, vomiting, diarrhea, or sore throat. No body aches
2 full weeks of mild to moderate headaches and fatigue. This is outside of the typical 36 hours that was told to us. I am a professional. I do not believe I have COVID. I do not believe I have another virus.
No adverse event; 9 patients received Moderna Covid-19 Bivalent vaccine vaccine past the 30 day beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (9 patients received Moderna Covid-19 Bivalent vaccine vaccine past the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7162B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 14-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 14-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (9 patients received Moderna Covid-19 Bivalent vaccine vaccine past the 30 day beyond use date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (9 patients received Moderna Covid-19 Bivalent vaccine vaccine past the 30 day beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (9 patients received Moderna Covid-19 Bivalent vaccine vaccine past the 30 day beyond use date).    Concomitant medication details not reported by the reporter. Patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. 9 patients received Moderna Covid-19 Bivalent vaccine vaccine past the 30 day beyond use date.  The vaccine was delivered to the hospital on September 20, 2022. 5 Patients received the vaccine on 14-NOV-2022, 2 patients received the vaccine on 15-NOV-2022 and the other 2 patients received the vaccine 22-DEC-2022. Treatment details was not reported by the reporter. This case contains information about patient 2nd out of 9 patients.    This case was linked to US-MODERNATX, INC.-MOD-2023-725025 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-725025:Master case
Day 1-Rash, Day 10-flu like symptoms, Day 14- unusually heavy/early menstruation, cannot maintain body temperature
Myalgia & Fever Narrative: Employee reported symptoms began 24 hours after vaccine and lasted for 24 hours
After 1st dose, she was really tired and slept for 2 days; After 1st dose, she was really tired and slept for 2 days; Her arm was very sore for 3 to 4 days; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSOMNIA (After 1st dose, she was really tired and slept for 2 days), PAIN IN EXTREMITY (Her arm was very sore for 3 to 4 days) and FATIGUE (After 1st dose, she was really tired and slept for 2 days) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure, Diabetes, Acid reflux (esophageal), Fibromyalgia and Allergy.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 08-Mar-2021, the patient experienced HYPERSOMNIA (After 1st dose, she was really tired and slept for 2 days) and PAIN IN EXTREMITY (Her arm was very sore for 3 to 4 days). On an unknown date, the patient experienced FATIGUE (After 1st dose, she was really tired and slept for 2 days). At the time of the report, HYPERSOMNIA (After 1st dose, she was really tired and slept for 2 days), PAIN IN EXTREMITY (Her arm was very sore for 3 to 4 days) and FATIGUE (After 1st dose, she was really tired and slept for 2 days) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications includes Allergy medicine, BP medicine, Diabetes medicine, Acid reflux medicine and Fibromyalgia medicine.    This case was linked to MOD-2021-069632 (Patient Link).
headache; body aches; slight bruising at injection site; This is a spontaneous report from a contactable consumer (patient). A 36-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (lot number and expiry date: unknown) as dose number unknown, single, for Covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On unspecified date, the patient experienced headache, body aches, and slight bruising at injection site. Outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information expected.
Pt reports that starting about 3 days after vaccination, he began developing pruritic rash, first in axillae, then groin, and  after receiving second COVID-19 vaccine on  2/14/21 (lot # O13M2OA ), rash increased. Pt was seen in clinic on 2/18/20 with  cluster of ~4 1cm, raised, erythematous nodular lesions lateral aspect of axilla bilat; few similar lesions upper arms, left scapula, inguinal-medial thighs bilat, right suprapubic area, lower legs, as well as few <1mm vesicular lesions on legs and groin,  excoriations noted on flanks, no intertrigenous lesions or linear tracking; no open lesion or crusting
This spontaneous report as received from a nurse practitioner refers to unspecified number of patients of unknown age. On an unknown date the patients were vaccinated with PROQUAD (Merck) (lot# and expiration date, route and dose were unknown) which were exposed to unspecified temperatures above 5F on unspecified dates. The nurse practitioner explained that the Department of Health informs facilities to call the manufacturer of vaccines when there had been 4 consecutive temperature readings above the recommended range; these temperature readings were recorded every 15 minutes. The specific temperatures and dates of the excursions were not specified, and it was not known whether or not the temperature excursions would be supported, since the nurse practitioner had not called the MNSC for stability when the freezer was recorded above 5F for fewer than 4 consecutive readings. She stated that she believes the non-reported temperature variances are defrost cycles. No adverse effects has been observed or reported. This is one of two reports from the same reporter (total patients number approximately 50). Additional information has been requested.
Information has been received from a physician concerning a female who was vaccinated with one dose of Varivax. (Site unknown) On 01/10/01, the physician's office received a telephone call that the patient had a temperature for three days approximately 01/10/02. The patient sought unspecified medical attention. The physician requested a lot check on the lot because there were "more phone calls than ever before". The records of testing prior to release of this lot have been checked and found to be satisfactory. This lot complies with the standard and was released. FOLLOW- UP information on 03/07/02, from a physician noted there were no more adverse events to report other than those that were previously reported. The physician started that the reason she used the phrase "more cells than ever", was  because she has been in practice for a number of years, and always gave patient/parent standard information on the benefits/risks of a vaccine before its administration, and also instructed them to call the office if the child experienced any problems post-vaccination. The physician reported that in her years of practice, it had been her experience that parents very rarely call their office to report a post-vaccination reaction. It was very unusual for their office to receive as many calls as they did in 01/02, including this patient and other patients who were vaccinated and experienced similar events (WAES0201UDSA03018, 0202USA00428, 0202USA00430, 0202USA431, 0202USA00432). The physician also thought it was unusual that several of the adverse events seemed to be occurring at day 10 post-vaccination. It was noted that there were no additional cases reported and the increase in calls was just in the month of 01/02. They did not experience any unusual volume of cells in 02/02 or  thus far in 03/ 02. Additioanl information has been requested.
Pt went to hospital 24 hours after vaccines with anaphylaxis (rash and facial edema). Pt also tried eggs earlier that day.
9:30 AM 15 min after receiving flu injection c/o "warm feeling and stiffness" in (R) arm. Reports usually occurs after inject. but "lasting longer this time" c/o pain in neck. BP 138/74. Pulse 76 Reg. Denies SOB, swelling, itching. 9:45 - pain in neck subsiding client took own ibuprofen (OTC).
On 3/27/01, complained of "flu-like" symptoms; nausea, low-grade fever, neck, shoulder and arm pain.
This spontaneous report as received from a nurse refers to unspecified number of patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. The nurse provided that in May 2016, she had a temperature excursion (to 34.4F for 8 hours and 24 minutes) with GARDASIL 9 (lot # L025737 with expiration date 28-JUL-2017). On unknown dates in 2016, the patients were administered the improperly stored doses of GARDASIL 9 (dose and route not reported). On an unknown date in 2016, the vaccines had a second excursion to 28.9F for 8 hours cycling every 20 minutes. No vaccines were administered since the second excursion. This is one of several reports received from the same reporter. Additional information has been requested.
Due to scheduling issues, he missed the second dose; A spontaneous report was received from a consumer concerning a 58-year-old, male patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and due to scheduling issues, he missed the second dose/ product dose omission issue.   The patient's medical history was not provided. No relevant concomitant medications were reported.    On 27-Jan-2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Batch Number: 007M20A) for prophylaxis of COVID-19 infection.   On an unspecified date, due to scheduling issues, the patient missed the second dose. The patient was more than 42 days post first dose and was not able to get the second dose.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the event, due to scheduling issues, he missed the second dose was considered resolved.; Sender's Comments: This report refers to a case of Missed Dose for mRNA-1273, lot #unknown with no associated AEs.
Patient presented to the office for a possible vaccine reaction. She had the meningococcal B and flu vaccines this morning. The vaccines were given around 10:30am this morning. About an hour ago (around 1:00pm), she started to have chills. Shortly afterward, she started shaking uncontrollably. Her mom was starting to get worried, so brought her back to the clinic. She is now feeling lightheaded/dizzy, nauseated, and getting a headache.  Denies erythema, itching, or rash. Denies itching, tingling or edema of lips, tongue, or throat. Denies hoarseness, shortness of breath (dyspnea), chest tightness, cough, or wheezing. Denies abdominal pain or diarrhea. Denies syncope, altered mental status, chest pain, or palpitations. Denies lethargy, or confusion.  While checking vitals, she began projectile vomiting.  HR 120bpm BP 110/70 Spo2 97% T 98.8 EMS called. Epinephrine 0.3mg IM given. Sent to ER via ambulance.
Immediate rash and intense itching over the entire body the next morning. Difficulty breathing starting 5 days after the vaccination. Raised hives over entire body. Symptoms disappear after taking a combination of allegra, famotidine, and xyzal as prescribed by allergist. Symptoms reappear as soon as antihistamines are stopped, symptoms have lasted for nearly a month.
burning sensation in his arm and shooting up his neck; This spontaneous case was reported by a pharmacist and describes the occurrence of BURNING SENSATION (burning sensation in his arm and shooting up his neck) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BURNING SENSATION (burning sensation in his arm and shooting up his neck). At the time of the report, BURNING SENSATION (burning sensation in his arm and shooting up his neck) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not provided.  Treatment information was not provided.
Fever of 101 on 9/1 (evening after vaccine). Fever of 100 on 9/2 (48-72 hours after vaccine).
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 01Sep2021 as dose 2, single (Batch/Lot number: unknown) at the age of 60 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Cancer history" (unspecified if ongoing); "all gerd reflux med" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Codiene, reaction(s): "Allergy"; Z pak, reaction(s): "Allergy". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Unknown results. Therapeutic measures were taken as a result of drug ineffective, covid-19 including PAXLOVID (Lot number: 1918528A) on 16Jul2022 to 20Jul2022.  The lot number for BNT162b2, was not provided and will be requested during follow-up.
Fainting  - within 5 minutes. Unresponsive x 30sec. - Responsive after
8/6 - received anthrax shot. 8/8 developed swelling and redness at site. No F/C 4x5cm size erythema and redness; The Patient is a 26-year-old female who received her anthrax vaccine on August 6, 2008 at 2:15 p.m. She started having some swelling and redness at the site on August 8, 2008 at 7:30 a.m. Some pain. Mild itching. Currently she has no other illnesses.